Skip to content
Disclosery

FCPM III SERVICES B.V.

Follow

13F filer, CIK 2013410, NAARDEN, Netherlands

FCPM III SERVICES B.V. reported $722,206,839 across 10 holdings for the quarter ended 2026-03-31, in a 13F-HR filed 2026-05-15.

Filed (acceptance time not in the bulk data set), ingested 13F-HR 0001193125-26-225423

Period
2026-03-31
Reported value
$722M
Holdings
10
Top 10 weight
100%
New
1
Sold out
1

Part of the filer group FCPM III SERVICES B.V.

How groups are built

Largest buys vs the previous quarter

SecurityShares changeApprox. value
DMRAnew+2,441,000$63.2M
VORadded+500,000$8.92M

Ranked by the share change valued at this quarter's implied price (value over shares in the 13F). A position sold out is valued at the previous quarter's price, its last report.

Largest sells vs the previous quarter

SecurityShares changeApprox. value
RAPTexited-1,833,333-$62.1M
DYNreduced-818,460-$14.8M

Ranked by the share change valued at this quarter's implied price (value over shares in the 13F). A position sold out is valued at the previous quarter's price, its last report.

Holdings, Q1 2026

Share positions as resolved from 13F-HR 0001193125-26-225423, largest first. % of portfolio is the value over $722,206,839, the sum of the share positions whose value is usable for ratios (method).

SecurityHistorySharesValue% of portfolioChangeLatest eventTimeline
NAMSNEWAMSTERDAM PHARMA COMPANYQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q2: restricted; 2024Q3: 11,831,461 shares; 2024Q4: 10,597,181 shares; 2025Q1: 10,935,310 shares; 2025Q2: 10,632,113 shares; 2025Q3: 9,212,384 shares; 2025Q4: 9,198,900 shares; 2026Q1: 9,198,900 shares 9,198,900$294M40.77%0Timeline
DYNDYNE THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q2: restricted; 2024Q3: 5,954,069 shares; 2024Q4: 5,462,846 shares; 2025Q1: 5,462,846 shares; 2025Q2: 5,462,846 shares; 2025Q3: 5,462,846 shares; 2025Q4: 5,462,846 shares; 2026Q1: 4,644,386 shares 4,644,386$84.2M11.66%-818,460Timeline
VORVOR BIOPHARMA INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: 379,640 shares; 2025Q4: 3,617,354 shares; 2026Q1: 4,117,354 shares 4,117,354$73.5M10.17%+500,000Timeline
ENGNENGENE HOLDINGS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q2: restricted; 2024Q3: 8,677,951 shares; 2024Q4: 9,632,561 shares; 2025Q1: 9,632,561 shares; 2025Q2: 9,632,561 shares; 2025Q3: 9,632,561 shares; 2025Q4: 9,632,561 shares; 2026Q1: 9,632,561 shares 9,632,561$65.6M9.08%0Timeline
MPLTMAPLIGHT THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: 3,226,400 shares; 2026Q1: 3,226,400 shares 3,226,400$65.6M9.08%0Timeline
DMRADAMORA THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: 2,441,000 shares 2,441,000$63.2M8.75%newTimeline
CBIOCRESCENT BIOPHARMA INC.Quarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: 1,677,852 shares; 2026Q1: 1,677,852 shares 1,677,852$30.8M4.27%0Timeline
REPLREPLIMUNE GROUP INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q2: restricted; 2024Q3: 4,866,449 shares; 2024Q4: 3,970,668 shares; 2025Q1: 3,909,696 shares; 2025Q2: 3,909,696 shares; 2025Q3: 4,158,368 shares; 2025Q4: 2,808,368 shares; 2026Q1: 2,808,368 shares 2,808,368$21.5M2.97%0Timeline
BCYCBICYCLE THERAPEUTICS PLCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q2: restricted; 2024Q3: 2,339,961 shares; 2024Q4: 3,452,330 shares; 2025Q1: 3,452,330 shares; 2025Q2: 3,452,330 shares; 2025Q3: 3,452,330 shares; 2025Q4: 3,468,430 shares; 2026Q1: 3,468,430 shares 3,468,430$16.1M2.23%0Timeline
ENGNWENGENE HOLDINGS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q2: restricted; 2024Q3: 2,878,148 shares; 2024Q4: 2,878,148 shares; 2025Q1: 2,878,148 shares; 2025Q2: 2,878,148 shares; 2025Q3: 2,878,148 shares; 2025Q4: 2,878,148 shares; 2026Q1: 2,878,148 shares 2,878,148$7.28M1.01%0Timeline

Sold out in Q1 2026

Positions in the previous quarter's report that this quarter's report no longer lists.

SecurityShares beforeValue beforeType
RAPTRAPT THERAPEUTICS INC1,833,333$62.1Mshares

How Q1 2026 was built

Available 13F filings of this filer for the quarter and their roles: the base report is the latest original or restatement, NEW HOLDINGS amendments filed after it are added (method).

FilingRoleAmendmentFiledAcceptedIngested
13F-HR 0001193125-26-225423 base2026-05-15acceptance time not in the bulk data set